Browse studies

Find your next paid study

27,306 recruiting studies available now

Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults With MammaPrint High 2 Risk (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients wit…

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8HER2-Negative Breast Carcinoma+1 more

Estimated

~$50 – $1,350

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT06058377

Evaluation of the Clinical Spectrum of Diabetes and Obesity in Youth and Adults

Background: Diabetes and obesity are chronic diseases. They can affect blood flow and how the body processes nutrients, and complications over time can lead t…

ObesityDiabetesMetabolic Disorders

Estimated

~$10 – $675

Actual pay is set by the research site.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT07388537

Phase 2

A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations

This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic n…

Pheochromocytoma/ParagangliomaPancreatic Neuroendocrine TumorVon Hippel-Lindau Disease+2 more

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Merck Sharp & Dohme LLC

Phase 2

A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial Comparing the Safety and Efficacy of Two Different Oral Vapendavir (VPV) Doses With Placebo as Treatment for Rhinovirus (RV) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Compare the safety and efficacy of two different oral vapendavir doses with placebo in order to determine the appropriate dose of vapendavir to reduce the seve…

Rhinovirus Infection

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Altesa Biosciences, Inc.NCT07610395

Human Specimen Collection to Support Basic and Clinical Research

The collection of human specimens from both patients and healthy volunteers is necessary for the development of laboratory assays to further basic and clinical…

Sickle Cell Disease

Estimated

~$10 – $675

Actual pay is set by the research site.

National Heart, Lung, and Blood Institute (NHLBI)NCT00047996

Observational

Exercise and Emotional Learning in Posttraumatic Stress Disorder

The goal of this clinical trial is to test how exercise affects learning and memory processes relevant to the treatment of PTSD. Participants will complete a b…

PTSD

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Christal L BadourNCT06127342

Observational

Precision Treatment to Promote Smoking Cessation and Survival in Oncology Patients

This study evaluates the feasibility and preliminary effects of precision tobacco treatment, compared to usual care, on promoting tobacco treatment in oncology…

Smoking CessationSmokingPhysician's Role

Estimated

~$10 – $750

Actual pay is set by the research site.

Washington University School of MedicineNCT07166120

Phase 2

A PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS

This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of …

Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer

Estimated

~$75 – $3,000

Actual pay is set by the research site.

PfizerNCT04606446

Phase 2

Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamo…

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+22 more

Phase 3

An Open-Label, Multicenter, Randomized, Non-Inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Weekly Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Patients With Alpha1-Antitrypsin Deficiency Compared to Corresponding Standard 60 mg/kg/Week and 120 mg/kg/Week Doses of Intravenous Alpha1-Proteinase Inhibitor (5%)

This study is designed to compare two different weekly doses of a medicine called Alpha1-Proteinase Inhibitor given by injection under the skin with the standa…

Alpha 1 Antitrypsin Deficiency

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Grifols Therapeutics LLCNCT07555483

Phase 1

A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-10726 in Patients With Advanced Malignancies

This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies. The study will be co…

Gastroesophageal Cancer (GC)Hepatocellular Carcinoma (HCC)Endometrial Cancer+1 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Compass TherapeuticsNCT07419841

Phase 2

A Phase 2, Open-Label, Multicenter, Randomized Trial Evaluating the Efficacy and Safety of Different Schedules of Neoadjuvant Pembrolizumab and Porustobart in Patients With Resectable pMMR/MSS Colon Cancer

The goal of this clinical trial is to learn if giving two medicines together, porustobart and pembrolizumab, before surgery can treat a common type of colon ca…

Colon Cancer

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Solstice Oncology, Inc.NCT07808151